Equillium (EQ) 10-K 27 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 26, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Document Fiscal Period Focus	FY
Trading Symbol	EQ
Entity Registrant Name	EQUILLIUM, INC.
Entity Central Index Key	0001746466
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock Shares Outstanding		17,376,236
Entity Public Float			$ 0

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 28,508,534	$ 7,103,553
Short-term investments	37,404,750	0
Prepaid expenses and other current assets	1,185,844	45,813
Total current assets	67,099,128	7,149,366
Property and equipment, net	63,515	2,077
Total assets	67,162,643	7,151,443
Current liabilities:
Accounts payable	1,119,150	243,741
Accrued expenses	908,827	325,079
Total current liabilities	2,027,977	568,820
Long-term convertible promissory notes		6,994,847
Long-term convertible promissory notes, related party		1,064,019
Biocon anti-dilution right		775,842
Other non-current liabilities	199,530
Total liabilities	2,227,507	9,403,528
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.0001 par value; 200,000,000 and 43,100,000 shares authorized at December 31, 2018 and December 31, 2017, respectively; 17,376,236 and 10,708,074 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively	789	124
Additional paid-in capital	80,441,417	9,665
Accumulated other comprehensive gain	5,279
Accumulated deficit	(15,512,349)	(2,261,874)
Total stockholders' equity (deficit)	64,935,136	(2,252,085)
Total liabilities and stockholders' equity (deficit)	$ 67,162,643	$ 7,151,443

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	43,100,000
Common stock, shares issued	17,376,236	10,708,074
Common stock, shares outstanding	17,376,236	10,708,074

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Operating expenses:
Research and development	$ 1,333,721	$ 4,943,149
General and administrative	378,328	3,672,438
Total operating expenses	1,712,049	8,615,587
Loss from operations	(1,712,049)	(8,615,587)
Other expense (income):
Interest expense	379,385	2,557,510
Interest income		(339,620)
Change in fair value of Biocon anti-dilution right	170,440	2,416,998
Total other expense (income)	549,825	4,634,888
Net loss	(2,261,874)	(13,250,475)
Other comprehensive income:
Unrealized gain on available-for-sale securities, net		5,279
Comprehensive loss	$ (2,261,874)	$ (13,245,196)
Net loss per share, basic and diluted	$ (0.22)	$ (1.09)
Weighted-average common shares outstanding, basic and diluted	10,106,760	12,190,245

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Total	IPO	Biocon	Founder Notes	Common Stock	Common StockIPO	Common StockBiocon	Common StockFounder Notes	Additional Paid-in Capital	Additional Paid-in CapitalIPO	Additional Paid-in CapitalBiocon	Accumulated Other Comprehensive Income	Accumulated Other Comprehensive IncomeFounder Notes	Accumulated Deficit
Balance at Mar. 15, 2017	$ 0
Issuance of common stock			$ 9,689	$ 100			$ 24	$ 100			$ 9,665
Issuance of founders stock, Shares								8,620,000
Issuance of common stock, Shares							2,088,074
Net loss	(2,261,874)													$ (2,261,874)
Balance at Dec. 31, 2017	(2,252,085)				$ 124				$ 9,665					(2,261,874)
Balance, Shares at Dec. 31, 2017					10,708,074
Issuance of common stock	44	$ 64,475,457	$ 3,192,841		$ 44	$ 512	$ 23			$ 64,474,945	$ 3,192,818
Issuance of common stock, Shares					446,171	5,115,097	228,060
Issuance of common stock upon conversion of promissory notes	12,303,760				$ 88				12,303,672
Issuance of common stock upon conversion of promissory notes, Shares					878,834
Fractional shares adjustment upon forward stock split	(197)				$ (2)				(195)
Vesting of restricted stock liability	18,598								18,598
Stock-based compensation expense	441,914								441,914
Comprehensive Income				$ 5,279									$ 5,279
Net loss	(13,250,475)													(13,250,475)
Balance at Dec. 31, 2018	$ 64,935,136				$ 789				$ 80,441,417			$ 5,279		$ (15,512,349)
Balance, Shares at Dec. 31, 2018					17,376,236

Statements of Stockholders' E_2

Statements of Stockholders' Equity (Deficit) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Offering costs	$ 2,123,106
Biocon
Sale of stock, price per share		$ 0.005

Statements of Cash Flows

Statements of Cash Flows - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Operating activities:
Net loss	$ (2,261,874)	$ (13,250,475)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	122	6,102
Stock-based compensation		441,914
Deferred rent		696
Non-cash interest expense	379,385	2,557,510
Change in fair value of Biocon anti-dilution right	170,440	2,416,998
Non-cash research license expense	615,091
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(45,813)	(1,140,031)
Accounts payable	243,740	842,722
Accrued expenses	236,708	598,314
Net cash used in operating activities	(662,201)	(7,526,250)
Investing activities:
Purchases of property and equipment	(2,199)	(34,858)
Purchases of short-term investments		(37,399,471)
Net cash used in investing activities	(2,199)	(37,434,329)
Financing activities:
Proceeds from public offering of common stock, net of $2,123,106 issuance costs		64,475,457
Proceeds from issuance of convertible promissory notes, net	6,767,853	1,599,012
Proceeds from issuance of convertible promissory notes related party, net	1,000,000
Proceeds from issuance of common stock	100
Proceeds from exercise of stock options, including early exercise		291,091
Net cash provided by financing activities	7,767,953	66,365,560
Net increase in cash and cash equivalents	7,103,553	21,404,981
Cash and cash equivalents at beginning of period		7,103,553
Cash and cash equivalents at end of period	7,103,553	28,508,534
Supplemental disclosures of noncash activities:
Issuance of common stock	$ 9,689
Amounts included in accounts payable for purchases of property and equipment		32,682
Conversion of convertible promissory notes into common stock		12,303,760
Biocon Anti-Dilution Right
Supplemental disclosures of noncash activities:
Issuance of common stock		$ 3,192,841

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical)	12 Months Ended
	Dec. 31, 2018USD ($)
Statement Of Cash Flows [Abstract]
Offering costs	$ 2,123,106

Organization and Accounting Pro

Organization and Accounting Pronouncements	12 Months Ended
	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Accounting Pronouncements	1. Organization and Accounting Pronouncements Description of Business Equillium, Inc. (the “Company”) was incorporated in the state of Delaware on March 16, 2017. The Company is engaged in the research and development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The Company has devoted substantially all of its efforts to organizing and staffing the company, business planning, raising capital, in-licensing rights to EQ001, conducting preclinical research, filing its initial Investigational New Drug application (“IND”) and commencing clinical development of EQ001. In addition, the Company has a limited operating history, has not generated revenues from its principal operations, and the sales and income potential of its business is unproven. Forward Stock Split On October 1, 2018, the Company implemented a 1-for-8.62 forward stock split of its outstanding common stock. No fractional shares were issued in connection with the stock split, and the par value and other terms of the common stock were not affected by the stock split. All share and per share amounts, including stock options and exercise prices for stock options, have been retroactively adjusted in these financial statements for all periods presented to reflect the forward stock split. Liquidity On October 16, 2018, the Company completed an initial public offering (“IPO”) selling 4,670,000 shares of common stock at an offering price of $14.00 per share. The Company received net proceeds of approximately $58.7 million, after deducting underwriting discounts, commissions and offering-related transaction cost In November 2018, the Company sold an aggregate of 445,097 shares of common stock pursuant to the underwriters’ partial exercise of their option to purchase additional shares As of December 31, 2018, the Company had $65.9 million in cash, cash equivalents and short-term investments. The Company has incurred significant operating losses and negative cash flows from operations. The Company expects to use its cash, cash equivalents, and short-term investments to fund research and development of EQ001 and working capital and other general corporate purposes. The Company does not expect to generate any revenues from product sales unless and until the Company successfully completes development and obtains regulatory approval for EQ001 or any future product candidate, which will not be for at least the next several years, if ever. Accordingly, until such time as the Company can generate significant revenue from sales of its product candidates, if ever, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, and collaboration and license agreements. However, the Company may not be able to secure additional financing or enter into such other arrangements in a timely manner or on favorable terms, if at all. The Company’s failure to raise capital or enter into such other arrangements when needed would have a negative impact on the Company’s financial condition and could force the Company to delay, reduce or terminate its research and development programs or other operations, or grant rights to develop and market product candidates that the Company would otherwise prefer to develop and market itself. Management believes that the Company’s cash, cash equivalents and short-term investments as of December 31, 2018 will be sufficient to fund operations for at least one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (“SEC” Basis of Presentation The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the SEC. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). Recent Accounting Pronouncements In February 2015, the FASB issued ASU 2016-02, Leases (Topic 842), In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230) In June 2018, the FASB issued ASU 2018-07, Improvements to Non-Employee Share-Based Payment Accounting (Topic 718) Revenue from Contracts with Customers (Topic 606) In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company plans to adopt the provisions of ASU 2018-13 in the first quarter of 2020, and the Company is currently evaluating the impact on the financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of the Company’s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk. Comprehensive Income (Loss) The Company is required to report all components of comprehensive income (loss), including net loss, in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency gains and losses. Other comprehensive income includes unrealized gains on available-for-sale securities, which was the only difference between net loss and comprehensive loss for the applicable periods. Cash and Cash Equivalents Cash and cash equivalents include cash in readily available checking and savings accounts, and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Short-Term Investments Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive income (loss) . The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets primarily represent amounts related to director and officer insurance and clinical trial agreements. Property and Equipment Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years, or the remaining term of the lease). Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. While the Company’s current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception. Accrued Research and Development Expense The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, the Company adjusts its rate of expense recognition if actual results differ from its estimates. The Company classifies its estimates for accrued research and development expenses as accrued expenses on the accompanying balance sheet. Research and Development Research and development expenses include salaries and related overhead expenses, external research and development expenses incurred under arrangements with third parties, costs related to in-licensing rights to EQ001 from Biocon SA (together with Biocon Limited, “Biocon”), costs of services performed by third parties, such as contract research organizations, and costs related to preparing and filing an IND with the U.S. Food and Drug Administration. Research and development costs are expensed as incurred. Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statement of operations. Deferred Rent Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company leases. The Company’s leases for its facilities provide for fixed increases in minimum annual rental payments. The total amount of rental payments due over the lease terms are being charged to rent expense ratably over the life of the leases. The Company classifies the current and non-current portion of deferred rent as accrued expenses and other non-current liabilities, respectively, on the accompanying balance sheet. Biocon Anti-Dilution Right The Company committed to issue to Biocon SA additional shares of common stock to maintain Biocon’s ownership interest at 19.5% of the diluted Company shares outstanding (as defined in the License Agreements (as defined below)) until the Company received aggregate cumulative gross proceeds from sales of equity securities of $15.0 million (“Biocon Anti-Dilution Right”). As an obligation existed to issue a variable number of shares and that obligation was not indexed to the Company’s common stock, the Biocon Anti-Dilution Right was classified as a liability in the accompanying balance sheet. The Biocon Anti-Dilution Right was recorded at fair value using the precedent transaction method. The fair value of the Biocon Anti-Dilution Right was re-measured at each financial reporting period with any changes in fair value recognized as a component of other expense (income). In connection with the Company’s IPO in October 2018 the liability was reclassified to stockholders’ equity (deficit) . Stock-Based Compensation The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates of certain assumptions, including the volatility of the Company’s common stock, the expected term of the Company’s stock options, the expected dividend yield and the fair value of the Company’s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected term of stock options was estimated using the “simplified method” for employee options as the Company has no no not not Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more- likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities include outstanding stock options under the Company’s equity incentive plan and have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year ended December 31, Period March 16, 2017 (inception) through December 31, 2018 2017 Common stock options 420,481 - Total 420,481 - Correction of Immaterial Error During the quarter ended December 31, 2018, the Company corrected previously reported weighted-average shares outstanding and basic and diluted net loss per share for the period March 16, 2017 (Inception) through December 31, 2017 due to an error identified. In accordance with Staff Accounting Bulletin (SAB) No. 99, Materiality, management evaluated the materiality of the error and concluded the error was immaterial to the previously filed financial statements. The correction of the immaterial error resulted in an increase to weighted-average shares outstanding of 2.1 million shares and a decrease of basic and diluted net loss per share from $0.28 to $0.22 for the period March 16, 2017 (Inception) through December 31, 2017.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 —Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 —Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 —Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). Financial assets measured at fair value on a recurring basis consist of the Company’s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and short-term investments consisted of U.S. treasury securities, agency securities and certificates of deposit . The The following table summarizes the Company’s assets that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy as of December 31, 2018: Fair Value Measurements Using Quoted Prices in Significant Significant Active Markets Other Unobservable December 31, for Identical Observable Inputs 2018 Assets (Level 1) Inputs (Level 2) (Level 3) Short-term investments: U.S. treasury securities $ 29,821,150 $ 29,821,150 $ - $ - Agency securities 5,658,600 - 5,658,600 - Certificates of deposit 1,925,000 1,925,000 - - Total $ 37,404,750 $ 31,746,150 $ 5,658,600 $ - As of December 31, 2017, the Company did not hold any Level 1, Level 2, or Level 3 financial assets that are recorded at fair value on a recurring basis. The carrying amounts of the Company’s financial instruments, including prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. The Company believes the fair value of its convertible promissory notes approximates its carrying value. As of December 31, 2018, there were no convertible promissory notes on the Company’s balance sheet. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. At December 31, 2018 and 2017, the Company had investments in money market funds of $12.6 million and $0 million, respectively, that were measured at fair value using the net asset value per share (or its equivalent) that have not been classified in the fair value hierarchy. The funds invest primarily in U.S. government securities. The Company estimated the fair value of its Biocon Anti-Dilution Right (see Note 6) at the time of issuance and remeasured it at each reporting date using the precedent transaction method. The precedent transaction method was applied to solve for the enterprise value of the Company under two scenarios: with the Biocon Anti-Dilution Right and without the Biocon Anti-Dilution Right. The resulting difference in the enterprise value under these two scenarios was the estimated fair value of the Biocon Anti-Dilution Right. The estimates used to determine the enterprise value of the Company were based, in part, on subjective assumptions. Fluctuations in the fair value of the Biocon Anti-Dilution Right were impacted by unobservable inputs, most significantly the estimated fair value of the Company and probability of achieving different financing scenarios. Prior to the IPO, changes in the estimated fair value of the Company and the probability of achieving different financing scenarios had a significant impact on the fair value of the Biocon Anti-Dilution Right. Financial liabilities measured at fair value on a recurring basis consist of the Biocon Anti-Dilution Right. As of December 31, 2018, and December 31, 2017, the carrying amount of the Biocon Anti-Dilution Right was $0 and $0.8 million, respectively, which approximates fair value and was determined based upon Level 3 inputs. As of December 31, 2018, and 2017, the Company did not hold any Level 1 or Level 2 financial liabilities that are recorded at fair value on a recurring basis. The following table presents activity for the Biocon Anti-Dilution Right measured at fair value using Level 3 unobservable inputs as of December 31, 2018 and 2017: Fair Value Measurements at Reporting Date Using Significant Unobservable Inputs (Level 3) Balance at March 16, 2017 (inception) $ - Issuance of Biocon Anti-Dilution Right 605,402 Changes in fair value reflected as change in fair value of Biocon Anti-Dilution Right 170,440 Balance at December 31, 2017 775,842 Changes in fair value reflected as change in fair value of Biocon Anti-Dilution Right 2,416,998 Conversion to common stock upon IPO (3,192,840 ) Balance at December 31, 2018 $ - In connection with the closing of the IPO, the Company issued to Biocon 228,060 shares of common stock in full satisfaction of the Biocon Anti-Dilution Right.

Short-term Investments

Short-term Investments	12 Months Ended
	Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]
Short-term Investments	4. Short-term Investments The following table summarizes the Company’s short-term investments accounted for as available-for-sale securities as of December 31, 2018: Maturity Amortized Unrealized Unrealized Estimated (in years) Cost Losses Gains Fair Value December 31, 2018 U.S. treasury securities 1 or less $ 29,818,479 $ - $ 2,671 $ 29,821,150 Agency securities >1 and <5 5,655,992 - 2,608 5,658,600 Certificates of deposit >1 and <5 1,925,000 - - 1,925,000 Total $ 37,399,471 $ - $ 5,279 $ 37,404,750 All of the Company’s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. All of the Company’s securities have a maturity within two years of the balance sheet date. As of December 31, 2017, the Company had no short-term investments. There were no impairments considered other-than-temporary during the year ended December 31, 2018, as it is management’s intention and ability to hold the securities until a recovery of the cost basis or recovery of fair value. Unrealized gains and losses are included in accumulated other comprehensive income (loss).

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment consist of the following: December 31, December 31, 2018 2017 Furniture & fixtures $ 23,283 $ - Machinery & lab equipment 23,686 - Computer equipment 22,770 2,199 Less accumulated depreciation and amortization (6,224 ) (122 ) Property and equipment, net $ 63,515 $ 2,077 Depreciation expense related to property and equipment was $6,102 and $122, for the year ended December 31, 2018 and the period March 16, 2017 (inception) through December 31, the period March 16, 2017 (inception) through December 31,

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consist of the following: December 31, December 31, 2018 2017 Accrued payroll and other employee benefits $ 559,541 $ 15,548 Clinical studies 244,506 - Other accruals 96,412 632 Preclinical studies 8,368 36,000 Accrued taxes - 184,527 Accrued interest - 88,372 Total accrued expenses $ 908,827 $ 325,079

Collaboration and License Agree

Collaboration and License Agreement	12 Months Ended
	Dec. 31, 2018
Collaboration And License Agreement [Abstract]
Collaboration and License Agreement	7. Collaboration and License Agreement In May 2017, the Company entered into a collaboration and license agreement, clinical supply agreement, investor rights agreement, and common stock purchase agreement (collectively “License Agreements”) with Biocon. Pursuant to the License Agreements, Biocon granted the Company an exclusive license in the United States and Canada (“Company Territory”) to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical composition or preparation containing or comprising EQ001 (“Biocon Product”) that uses Biocon technology or Biocon know-how. Pursuant to the License Agreements, Biocon agreed to be the Company’s exclusive supplier of EQ001 clinical drug product. Biocon will provide clinical drug product at no cost for up to three concurrent orphan indications until the Company’s first U.S. regulatory approval and all other clinical drug product at Biocon’s cost. In consideration of the rights granted to the Company by Biocon, the Company issued Biocon shares of its common stock equal to 19.5% of its outstanding shares at the time of the execution of the License Agreements. Biocon also had a Biocon Anti-Dilution Right (see Note 2) which was recorded at fair value using the precedent transaction method (see Note 3) and was determined to be $605,402 at the time of issuance. As an obligation existed to issue a variable number of shares and such obligation was not indexed to the Company’s common stock, the Biocon Anti-Dilution Right was classified as a liability in the accompanying balance sheet. The fair value of the Biocon Anti-Dilution Right was re-measured at each financial reporting period with any changes in fair value being recognized as a component of other expense (income). In connection with the closing of the IPO, the Company issued to Biocon 228,060 shares of common stock in full satisfaction of the Biocon Anti-Dilution Right. In addition, the Company is obligated to pay Biocon up to an aggregate of $30 million in regulatory milestone payments upon the achievement of certain regulatory approvals and up to an aggregate of $565 million in sales milestone payments upon the achievement of first commercial sale of product and specified levels of product sales. The Company is also required to pay quarterly tiered royalties based on a percentage from the mid-single digits to sub-teen double-digits of net sales of Biocon Products, subject to adjustments in certain circumstances. Biocon is also required to pay the Company royalties at comparable percentages for sales of EQ001 outside of the Company Territory if the approvals in such geographies included or referenced the Company’s data. To date, the Company has not made or received payments in connection with the milestones or royalties within the agreement.

Convertible Promissory Notes

Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Convertible Promissory Notes	8. Convertible Promissory Notes In May 2017, the Company issued $1,000,000 in convertible promissory notes to its founders (“Founder Notes”). The Founder Notes accrued interest at a rate of 6% a year and had a maturity one year from issuance. The Founder Notes were convertible at the option of the holder upon a Qualified Financing (as defined below). In October 2017, November 2017, April 2018, and June 2018, the Company entered into note purchase agreements whereby the Company agreed to issue and investors (the “Noteholders”) agreed to purchase $9,407,474 in convertible promissory notes (the “Convertible Promissory Notes”). As part of the October 2017 Convertible Promissory Notes, the Founder Notes were amended and restated on terms matching the Convertible Promissory Notes and the then outstanding principal and accrued interest thereunder was included as the principal amount of each such amended and restated Convertible Promissory Note. The Convertible Promissory Notes accrued interest at a rate of 6% per year and had a maturity two years from their issuance. Pursuant to their terms, the Convertible Promissory Notes had an automatic conversion feature into equity securities sold pursuant to a qualified financing (“Qualified Financing”) transaction from which the Company would receive total gross proceeds of not less than $15.0 million. The conversion price was equal to 90% of the per share price paid by investors for such securities if the closing of the financing occurred on or prior to the six month anniversary of the issuance of Convertible Promissory Notes or equal to 80% of the per share price paid by investors for such securities if the closing of the financing occurred after the six month anniversary of the issuance of Convertible Promissory Notes. In connection with the closing of the IPO, the Convertible Promissory Notes converted into 878,834 shares of common stock. The Company recorded interest expense of $2,557,510 and $379,385 using the effective-interest method for the year ended December 31, 2018 and the period March 16, 2017 (inception) through December 31, 2017, respectively, in relation to stated interest and the estimated discount at which the Convertible Promissory Notes would convert. The following is a summary of all debt obligations recorded on the balance sheet at December 31, 2018 and 2017: December 31, December 31, 2018 2017 Convertible Promissory Notes $ - $ 7,807,474 Accrued discount - 251,392 Total notes payable $ - $ 8,058,866

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders’ Equity (Deficit)	9. Stockholders’ Equity (Deficit) During 2017, the Company issued 8,620,000 shares of common stock to founders at a price of $0.00001 per share and 2,088,074 shares of common stock to Biocon as partial consideration for the License Agreements (Note 7). The shares issued to Biocon were valued at $0.005 per share, resulting in $9,689 of research license expense. On October 16, 2018, the Company completed an IPO, selling 4,670,000 shares of common stock at an offering price of $14.00 per share. The Company received net proceeds of approximately $58.7 million, after deducting underwriting discounts, commissions and offering-related transaction costs. In connection with the closing of the IPO in October 2018, the Convertible Promissory notes automatically converted into an aggregate of 878,834 shares of the Company’s common stock and the Company issued 228,060 shares of common stock to Biocon pursuant to certain anti-dilution rights. In November aggregate of 445,097 shares of common stock pursuant to the underwriters’ partial exercise of their option to purchase additional shares Stock Options In December 2017, the Company adopted the 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. In October 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 Plan”) as the successor to and continuation of the 2017 Plan. No further grants will be made under the 2017 Plan. The 2018 Plan became effective in connection with the execution and delivery of the underwriting agreement related to the IPO. The 2018 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other forms of stock awards. Initially, the maximum number of shares of the Company’s common stock that may be issued under the 2018 Plan is 2,229,773 shares which consists of 333,119 shares of common stock reserved for issuance under the 2017 Plan at the time the 2018 Plan was adopted, 1,040,000 new shares of common stock approved for issuance under the 2018 Plan and 856,654 shares underlying awards granted under the 2017 Plan that were outstanding as of the effective date of the 2018 Plan and which will be added to the 2018 Plan’s reserve if such awards expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to meet a contingency or condition required to vest such shares or are reacquired, withheld or not issued to satisfy a tax withholding or to satisfy a purchase price or exercise price of a stock award. As of December 31, 2018, the number of shares reserved under the 2018 Plan was 1,363,119 shares. The number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2019 through January 1, 2028, in an amount equal to 5.0% of the total number of shares of the Company’s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors. The maximum number of shares of the Company’s common stock that may be issued on the exercise of incentive stock options under the Company’s 2018 Plan is 6,689,319. Options granted under the 2018 Plan and 2017 Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their date of grant. The exercise price of each option shall be determined by the Board of Directors based on the estimated fair value of the Company’s stock on the date of the option grant. The exercise price shall not be less than 100% of the fair market value of the Company’s common stock at the time the option is granted. Most option grants generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years and early exercise is permitted. A summary of the Company’s stock option activity under the 2018 Plan and 2017 Plan are as follows: Shares Weighted- Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2017 - $ - - $ - Granted 866,654 2.16 Exercised (446,171 ) (0.66 ) Cancelled - - Outstanding at December 31, 2018 420,483 $ 3.75 9.67 $ 1,853,746 Options exercisable at December 31, 2018 - $ - - $ - T he weighted-average fair value of options granted for the year ended December 31, 2018 and for the period March 16, 2017 (Inception) through December 31, 2017, were $5.79 and $0, respectively. The following table summarizes certain information regarding stock options: Year Ended December 31, Period March 16, 2017 (Inception) through December 31 2018 2017 Fair value of options vested during the period $ 46,080 $ - Cash received from options exercised during the period $ 291,091 $ - Intrinsic value of options exercised during the period $ 3,345,710 $ - 2018 Employee Stock Purchase Plan In October 2018, the Company adopted the 2018 Equity Stock Purchase Plan (“ESPP”). The ESPP became effective in connection with the execution and delivery of the underwriting agreement related to the IPO. The ESPP authorizes the issuance of 343,275 shares of the Company’s common stock under purchase rights granted to the Company’s employees or to employees of any of the Company’s designated affiliates. The number of shares of the Company’s common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2019 through January 1, 2028, by the lesser of (1) 1.0% of the total number of shares of the Company’s common stock outstanding on the last day of the calendar month before the date of the automatic increase, and (2) 343,275 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (1) and (2). Liability for Early Exercise of Restricted Stock Options All stock option grants under the 2017 Plan provide for exercise of the stock option prior to vesting. Shares of common stock issued upon exercise of unvested options are subject to repurchase by the Company at the respective original exercise price until vested. Consideration received for the exercise of unvested stock options is recorded as a liability and reclassified into equity as the related award vests. As of December 31, 2018, 446,171 unvested shares issued under early exercise provisions were subject to repurchase by the Company. The balance sheet reflects an unvested stock liability of $0.3 million and $0 million as of December 31, 2018 and 2017, respectively. The short-term portion of the unvested stock liability totals $0.1 million and is classified as accrued expenses on the accompanying balance sheet. The long-term portion of the unvested stock liability totals $0.2 million and is classified as other non-current liabilities on the accompanying balance sheet. Stock-Based Compensation Expense The allocation of stock-based compensation for all stock awards is as follows: Year Ended December 31, Period March 16, 2017 (Inception) through December 31 2018 2017 Research and development $ 250,701 $ - General and administrative 191,213 - Total $ 441,914 $ - The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows: Year Ended December 31, Period March 16, 2017 (Inception) through December 31, 2018 2017 Risk-free interest rate 2.83% - Expected volatility 88.29% - Expected term (in years) 5.91 - Expected dividend yield 0% - Risk-free interest rate. The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company’s stock options. Expected volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility as a private company, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. Expected term. The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options. Expected dividend yield. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. Forfeitures . The Company reduces stock-based compensation expense for actual forfeitures during the period. As of December 31, 2018 and 2017, the unrecognized compensation cost related to unvested stock option grants Common Stock Reserved for Future Issuance Common stock reserved for future issuance consists of the following as of December 31, 2018 and 2017: December 31, December 31, 2018 2017 Stock options issued and outstanding 420,483 - Awards available under the 2017 Plan - 1,189,773 Awards available under the 2018 Plan 1,363,119 - Employee stock purchase plan 343,275 - Total 2,126,877 1,189,773

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related-Party Transactions	10. Related-Party Transactions In May 2017, the Company entered into License Agreements with Biocon, a pharmaceutical company in which the Company’s Chief Executive Officer is on the Board of Directors. In May 2017, the Company entered into Founder Notes with the Company’s Chief Executive Officer and Chief Business Officer in the amounts of $500,000 and $500,000, respectively. These Founder Notes were subsequently amended and restated on terms matching the Convertible Promissory Notes and the then outstanding principal and accrued interest thereunder was included as the principal amount of each such amended and restated Convertible Promissory Note.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Leases and Other Commitments The Company leases certain office space in La Jolla, California under a non-cancelable operating lease, with a term through February 2022. Rent expense was $49,255 and $0 for the year ended December 31, 2018, and the period March 16, 2017 (inception) through The future minimum lease payments required under non-cancelable leases as of December 31, 2018, are summarized as follows: Year Ending December 31, 2019 $ 57,522 2020 58,914 2021 59,192 2022 9,865 2023 - Total minimum lease payments $ 185,493 The Company enters into service agreements with indemnification clauses in the ordinary course of business. Pursuant to such clauses, the Company indemnifies, defends, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by third party claims arising out of the indemnified party’s Litigation As of December 31, 2018 and 2017 there was no litigation against the Company .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The Company has not recorded a current or deferred tax expense or benefit for the year ended December 31, 2018 and the period March 16, 2017 (Inception) through December 31, 2017. A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 21% and 34% for the year ended December 31, 2018 and for the period March 16, 2017 (inception) through December 31, 2017, respectively, is as follows: Year Ended December 31, Period March 16, 2017 (Inception) through December 31, 2018 2017 Income taxes at statutory rates 21.00 % 34.00 % State income tax, net of federal benefit 0.00 % 0.00 % Permanent items -9.76 % -10.92 % Tax law change - tax reform 0.00 % -8.78 % Federal research credit 1.68 % 0.41 % Change in federal valuation allowance -12.92 % -14.71 % 0 % 0 % The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2018 and 2017 are as follows: December 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carryforward $ 2,268,242 $ 248,222 Credits 333,527 43,162 Intangibles 184,847 Other 224,534 198,290 Total deferred tax assets 3,011,150 489,674 Valuation allowance (3,010,878 ) (489,585 ) Total deferred tax assets, net of allowance $ 272 $ 89 Deferred tax liabilities: Property and equipment (272 ) (89 ) Total deferred tax liabilities $ (272 ) $ (89 ) Net deferred taxes $ - $ - The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of $3,010,878 as of December 31, 2018 as it does not believe it is more likely than not that certain deferred tax assets will be realized primarily due to the generation of pre-tax book losses in the current year, the lack of feasible tax-planning strategies, the limited existing taxable temporary differences, and the subjective nature of forecasting future taxable income into the future. The Company increased its valuation allowance by approximately $2,521,293 during the year ended December 31, 2018. At December 31, 2018, the Company had federal and California tax loss carry forwards of approximately $8,011,776, and $8,176,000, respectively. The federal and state net operating loss carry forwards begin to expire in 2037 unless previously utilized. The federal net operating loss carryover includes $7,127,000 of net operating losses generated in 2018. Federal net operating losses generated in 2018 carryover indefinitely and may generally be used to offset up to 80% of future taxable income. At December 31, 2018, the Company had federal and state tax credit carry forwards of approximately $305,035 and $141,611, respectively, after reduction for uncertain tax positions. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2037, if unused, and the state credits carry forward indefinitely. Pursuant to the Internal Revenue Code of 1986, as amended (“IRC”), specifically Section 382 and 383, the Company's ability to use net operating loss and research and development tax credit carry forwards (“tax attribute carry forwards”) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carry forwards available In December 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted. The Tax Act includes a number of changes to existing U.S. tax laws that impact the company, most notably a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017. The Tax Act also provides for the acceleration of depreciation for certain assets placed in service after September 27, 2017 as well as prospective changes beginning in 2018, including limitations on the deductibility of interest and capitalization of research and development expenditures. The SEC staff issued SAB 118, which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. The Tax Act reduced the Company’s corporate tax rate to 21 percent, effective January 1, 2018. In connection with the Company's initial analysis of the impact of the Tax Act, the Company reduced deferred tax assets by $198,687 which was offset by a reduction in the valuation allowance for the period March 16, 2017 (inception) through December 31, 2017. The Company has completed its accounting for the income tax effects of the Tax Act and there were no additional material impacts from the Company's initial analysis. The following table summarizes the reconciliation of the unrecognized tax benefits activity during the year ended December 31, 2018 and the period March 16, 2017 (inception) through December 31, 2017: Year Ended December 31, For the Period March 16, 2017 (Inception) through December 31, 2018 2017 Unrecognized Tax Benefits – Beginning $ 18,849 $ - Gross increases – tax positions in prior period - - Gross decreases – tax positions in prior period (11,310 ) - Gross increase – current-period tax positions 81,789 18,849 Gross decrease – current-period tax positions - - Settlements - - Lapse of statute of limitations - - Unrecognized Tax Benefits – Ending $ 89,328 $ 18,849 The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months. The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company's balance sheets as of December 31, 2018 and has not recognized interest and/or penalties in the statement of operations for the year ended December 31, 2018. All tax years for both federal and state purposes remain open and subject to examination by tax jurisdictions.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Retirement Plan	13. Retirement Plan The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the IRC. Participating employees may defer up to the Internal Revenue Service annual contribution limit. The Company has not made any contributions for the year ended December 31, 2018

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	14. Selected Quarterly Financial Data (unaudited) The following table contains unaudited quarterly financial information for the year ended December 31, 2018 and the period March 16, 2017 (inception) through December 31, 2017. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. First Quarter Second Quarter Third Quarter Fourth Quarter Year Ended December 31, 2018 Operating expenses $ (1,036,530 ) $ (1,125,078 ) $ (2,225,880 ) $ (4,228,099 ) Net loss (1,576,796 ) (1,765,363 ) (4,916,423 ) (4,991,893 ) Net loss per common share, basic and diluted $ (0.15 ) $ (0.16 ) $ (0.44 ) $ (0.31 ) Period March 16, 2017 (Inception) Through December 31, 2017 Operating expenses $ (67,195 ) $ (921,341 ) $ (83,711 ) $ (639,801 ) Net loss (67,195 ) (947,297 ) (141,025 ) (1,106,357 ) Net loss per common share, basic and diluted $ (0.01 ) $ (0.10 ) $ (0.01 ) $ (0.10 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events In January 2019, the Company created a new subsidiary in Australia with the Company serving as the sole shareholder through the subscription of shares. On February 27, 2019, the Company entered into a lease for approximately 2,050 square feet of office space located in South San Francisco, California. The commencement date of the lease is March 1, 2019. The term of the lease is two years. Future minimum obligations under the lease are $74,000, $91,000 and $15,000 for the years ended December 31, 2019, 2020, and 2021, respectively.

Organization and Accounting P_2

Organization and Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2015, the FASB issued ASU 2016-02, Leases (Topic 842), In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230) In June 2018, the FASB issued ASU 2018-07, Improvements to Non-Employee Share-Based Payment Accounting (Topic 718) Revenue from Contracts with Customers (Topic 606) In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company plans to adopt the provisions of ASU 2018-13 in the first quarter of 2020, and the Company is currently evaluating the impact on the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Concentration of Credit Risk and Off-Balance Sheet Risk	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company is required to report all components of comprehensive income (loss), including net loss, in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency gains and losses. Other comprehensive income includes unrealized gains on available-for-sale securities, which was the only difference between net loss and comprehensive loss for the applicable periods.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash in readily available checking and savings accounts, and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.
Short-Term Investments	Short-Term Investments Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive income (loss) . The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets primarily represent amounts related to director and officer insurance and clinical trial agreements.
Property and Equipment	Property and Equipment Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years, or the remaining term of the lease).
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. While the Company’s current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception.
Accrued Research and Development Expense	Accrued Research and Development Expense The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, the Company adjusts its rate of expense recognition if actual results differ from its estimates. The Company classifies its estimates for accrued research and development expenses as accrued expenses on the accompanying balance sheet.
Research and Development	Research and Development Research and development expenses include salaries and related overhead expenses, external research and development expenses incurred under arrangements with third parties, costs related to in-licensing rights to EQ001 from Biocon SA (together with Biocon Limited, “Biocon”), costs of services performed by third parties, such as contract research organizations, and costs related to preparing and filing an IND with the U.S. Food and Drug Administration. Research and development costs are expensed as incurred.
Patent Costs	Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statement of operations.
Deferred Rent	Deferred Rent Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company leases. The Company’s leases for its facilities provide for fixed increases in minimum annual rental payments. The total amount of rental payments due over the lease terms are being charged to rent expense ratably over the life of the leases. The Company classifies the current and non-current portion of deferred rent as accrued expenses and other non-current liabilities, respectively, on the accompanying balance sheet.
Biocon Anti-Dilution Right	Biocon Anti-Dilution Right The Company committed to issue to Biocon SA additional shares of common stock to maintain Biocon’s ownership interest at 19.5% of the diluted Company shares outstanding (as defined in the License Agreements (as defined below)) until the Company received aggregate cumulative gross proceeds from sales of equity securities of $15.0 million (“Biocon Anti-Dilution Right”). As an obligation existed to issue a variable number of shares and that obligation was not indexed to the Company’s common stock, the Biocon Anti-Dilution Right was classified as a liability in the accompanying balance sheet. The Biocon Anti-Dilution Right was recorded at fair value using the precedent transaction method. The fair value of the Biocon Anti-Dilution Right was re-measured at each financial reporting period with any changes in fair value recognized as a component of other expense (income). In connection with the Company’s IPO in October 2018 the liability was reclassified to stockholders’ equity (deficit) .
Stock-Based Compensation	Stock-Based Compensation The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates of certain assumptions, including the volatility of the Company’s common stock, the expected term of the Company’s stock options, the expected dividend yield and the fair value of the Company’s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. no no not not
Income Tax	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more- likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities include outstanding stock options under the Company’s equity incentive plan and have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year ended December 31, Period March 16, 2017 (inception) through December 31, 2018 2017 Common stock options 420,481 - Total 420,481 -
Correction of Immaterial Error	Correction of Immaterial Error During the quarter ended December 31, 2018, the Company corrected previously reported weighted-average shares outstanding and basic and diluted net loss per share for the period March 16, 2017 (Inception) through December 31, 2017 due to an error identified. In accordance with Staff Accounting Bulletin (SAB) No. 99, Materiality, management evaluated the materiality of the error and concluded the error was immaterial to the previously filed financial statements. The correction of the immaterial error resulted in an increase to weighted-average shares outstanding of 2.1 million shares and a decrease of basic and diluted net loss per share from $0.28 to $0.22 for the period March 16, 2017 (Inception) through December 31, 2017.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share	Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year ended December 31, Period March 16, 2017 (inception) through December 31, 2018 2017 Common stock options 420,481 - Total 420,481 -

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Summary of Assets Require Fair Value Measurements on a Recurring Basis and Input Levels Based on Fair Value Hierarchy	The following table summarizes the Company’s assets that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy as of December 31, 2018: Fair Value Measurements Using Quoted Prices in Significant Significant Active Markets Other Unobservable December 31, for Identical Observable Inputs 2018 Assets (Level 1) Inputs (Level 2) (Level 3) Short-term investments: U.S. treasury securities $ 29,821,150 $ 29,821,150 $ - $ - Agency securities 5,658,600 - 5,658,600 - Certificates of deposit 1,925,000 1,925,000 - - Total $ 37,404,750 $ 31,746,150 $ 5,658,600 $ -
Summary of Activity for the Biocon Anti-Dilution Right Measured at Fair Value Using Level 3 Unobservable Inputs	The following table presents activity for the Biocon Anti-Dilution Right measured at fair value using Level 3 unobservable inputs as of December 31, 2018 and 2017: Fair Value Measurements at Reporting Date Using Significant Unobservable Inputs (Level 3) Balance at March 16, 2017 (inception) $ - Issuance of Biocon Anti-Dilution Right 605,402 Changes in fair value reflected as change in fair value of Biocon Anti-Dilution Right 170,440 Balance at December 31, 2017 775,842 Changes in fair value reflected as change in fair value of Biocon Anti-Dilution Right 2,416,998 Conversion to common stock upon IPO (3,192,840 ) Balance at December 31, 2018 $ -

Short-term Investments (Tables)

Short-term Investments (Tables)	12 Months Ended
	Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]
Schedule of Company’s Short-Term Investments	The following table summarizes the Company’s short-term investments accounted for as available-for-sale securities as of December 31, 2018: Maturity Amortized Unrealized Unrealized Estimated (in years) Cost Losses Gains Fair Value December 31, 2018 U.S. treasury securities 1 or less $ 29,818,479 $ - $ 2,671 $ 29,821,150 Agency securities >1 and <5 5,655,992 - 2,608 5,658,600 Certificates of deposit >1 and <5 1,925,000 - - 1,925,000 Total $ 37,399,471 $ - $ 5,279 $ 37,404,750

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following: December 31, December 31, 2018 2017 Furniture & fixtures $ 23,283 $ - Machinery & lab equipment 23,686 - Computer equipment 22,770 2,199 Less accumulated depreciation and amortization (6,224 ) (122 ) Property and equipment, net $ 63,515 $ 2,077

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: December 31, December 31, 2018 2017 Accrued payroll and other employee benefits $ 559,541 $ 15,548 Clinical studies 244,506 - Other accruals 96,412 632 Preclinical studies 8,368 36,000 Accrued taxes - 184,527 Accrued interest - 88,372 Total accrued expenses $ 908,827 $ 325,079

Convertible Promissory Notes (T

Convertible Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Summary of All Debt Obligations Recorded on Balance Sheet	The following is a summary of all debt obligations recorded on the balance sheet at December 31, 2018 and 2017: December 31, December 31, 2018 2017 Convertible Promissory Notes $ - $ 7,807,474 Accrued discount - 251,392 Total notes payable $ - $ 8,058,866

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Stock Option Activity	The following table summarizes certain information regarding stock options: Year Ended December 31, Period March 16, 2017 (Inception) through December 31 2018 2017 Fair value of options vested during the period $ 46,080 $ - Cash received from options exercised during the period $ 291,091 $ - Intrinsic value of options exercised during the period $ 3,345,710 $ -
Summary of Stock-Based Compensation	The allocation of stock-based compensation for all stock awards is as follows: Year Ended December 31, Period March 16, 2017 (Inception) through December 31 2018 2017 Research and development $ 250,701 $ - General and administrative 191,213 - Total $ 441,914 $ -
Summary of Weighted-Average Assumptions Used to Determine Fair Value of Stock Option Grants	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows: Year Ended December 31, Period March 16, 2017 (Inception) through December 31, 2018 2017 Risk-free interest rate 2.83% - Expected volatility 88.29% - Expected term (in years) 5.91 - Expected dividend yield 0% -
Summary of Reserved Shares of Common Stock for Future Issuance	Common stock reserved for future issuance consists of the following as of December 31, 2018 and 2017: December 31, December 31, 2018 2017 Stock options issued and outstanding 420,483 - Awards available under the 2017 Plan - 1,189,773 Awards available under the 2018 Plan 1,363,119 - Employee stock purchase plan 343,275 - Total 2,126,877 1,189,773
2018 and 2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Stock Option Activity	A summary of the Company’s stock option activity under the 2018 Plan and 2017 Plan are as follows: Shares Weighted- Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2017 - $ - - $ - Granted 866,654 2.16 Exercised (446,171 ) (0.66 ) Cancelled - - Outstanding at December 31, 2018 420,483 $ 3.75 9.67 $ 1,853,746 Options exercisable at December 31, 2018 - $ - - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Lease Payments Required Under Non-Cancelable Leases	The future minimum lease payments required under non-cancelable leases as of December 31, 2018, are summarized as follows: Year Ending December 31, 2019 $ 57,522 2020 58,914 2021 59,192 2022 9,865 2023 - Total minimum lease payments $ 185,493

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Total Income Tax Provision Tax Rate to Statutory Federal Income Tax Rate	A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 21% and 34% for the year ended December 31, 2018 and for the period March 16, 2017 (inception) through December 31, 2017, respectively, is as follows: Year Ended December 31, Period March 16, 2017 (Inception) through December 31, 2018 2017 Income taxes at statutory rates 21.00 % 34.00 % State income tax, net of federal benefit 0.00 % 0.00 % Permanent items -9.76 % -10.92 % Tax law change - tax reform 0.00 % -8.78 % Federal research credit 1.68 % 0.41 % Change in federal valuation allowance -12.92 % -14.71 % 0 % 0 %
Significant Components of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2018 and 2017 are as follows: December 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carryforward $ 2,268,242 $ 248,222 Credits 333,527 43,162 Intangibles 184,847 Other 224,534 198,290 Total deferred tax assets 3,011,150 489,674 Valuation allowance (3,010,878 ) (489,585 ) Total deferred tax assets, net of allowance $ 272 $ 89 Deferred tax liabilities: Property and equipment (272 ) (89 ) Total deferred tax liabilities $ (272 ) $ (89 ) Net deferred taxes $ - $ -
Summary of Reconciliation of Unrecognized Tax Benefits	The following table summarizes the reconciliation of the unrecognized tax benefits activity during the year ended December 31, 2018 and the period March 16, 2017 (inception) through December 31, 2017: Year Ended December 31, For the Period March 16, 2017 (Inception) through December 31, 2018 2017 Unrecognized Tax Benefits – Beginning $ 18,849 $ - Gross increases – tax positions in prior period - - Gross decreases – tax positions in prior period (11,310 ) - Gross increase – current-period tax positions 81,789 18,849 Gross decrease – current-period tax positions - - Settlements - - Lapse of statute of limitations - - Unrecognized Tax Benefits – Ending $ 89,328 $ 18,849

Selected Quarterly Financial _2

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	The operating results for any quarter are not necessarily indicative of results for any future period. First Quarter Second Quarter Third Quarter Fourth Quarter Year Ended December 31, 2018 Operating expenses $ (1,036,530 ) $ (1,125,078 ) $ (2,225,880 ) $ (4,228,099 ) Net loss (1,576,796 ) (1,765,363 ) (4,916,423 ) (4,991,893 ) Net loss per common share, basic and diluted $ (0.15 ) $ (0.16 ) $ (0.44 ) $ (0.31 ) Period March 16, 2017 (Inception) Through December 31, 2017 Operating expenses $ (67,195 ) $ (921,341 ) $ (83,711 ) $ (639,801 ) Net loss (67,195 ) (947,297 ) (141,025 ) (1,106,357 ) Net loss per common share, basic and diluted $ (0.01 ) $ (0.10 ) $ (0.01 ) $ (0.10 )

Organization and Accounting P_3

Organization and Accounting Pronouncements - Additional Information (Details)	Nov. 15, 2018USD ($)shares	Oct. 16, 2018USD ($)$ / sharesshares	Nov. 30, 2018USD ($)shares	Oct. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)shares
Organization And Accounting Pronouncements [Line Items]
Date of incorporation						Mar. 16, 2017
State of incorporation						Delaware
Net proceeds, after deducting underwriting discounts, commissions and related transaction costs						$ 64,475,457
Proceeds from issuance of common stock					$ 100
Cash, Cash equivalents and short-term investments						$ 65,900,000
Underwriters Option
Organization And Accounting Pronouncements [Line Items]
Sale of stock | shares	445,097		445,097
Proceeds from issuance of common stock	$ 5,800,000		$ 5,800,000
Common Stock
Organization And Accounting Pronouncements [Line Items]
Forward stock split, conversion ratio				8.62
Sale of stock | shares						446,171
Common Stock | IPO
Organization And Accounting Pronouncements [Line Items]
Sale of stock | shares		4,670,000		4,670,000		5,115,097
Sale of stock, price per share | $ / shares		$ 14		$ 14
Net proceeds, after deducting underwriting discounts, commissions and related transaction costs		$ 58,700,000		$ 58,700,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended							10 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2018	May 31, 2017
Summary Of Significant Accounting Policies [Line Items]
Dividends										$ 0
Net loss per share, basic and diluted	$ 0.01	$ 0.31	$ 0.44	$ 0.16	$ 0.15	$ 0.10	$ 0.01	$ 0.10	$ 0.22	$ 1.09
Correction of Immaterial Error
Summary Of Significant Accounting Policies [Line Items]
Increase in weighted- average shares outstanding									2.1
Net loss per share, basic and diluted									$ 0.28
Collaboration and License Agreement | Biocon Anti-Dilution Right
Summary Of Significant Accounting Policies [Line Items]
Percentage of common stock outstanding shares issued in consideration for collaboration and license agreement		19.50%								19.50%	19.50%
Aggregate cumulative gross proceeds from sales of equity securities to be received		$ 15,000,000								$ 15,000,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful lives										3 years
Percentage of tax benefit to be realized upon ultimate settlement with tax authority										50.00%
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful lives										5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share (Details)	12 Months Ended
	Dec. 31, 2018shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted net loss per share	420,481
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities not included in calculation of diluted net loss per share	420,481

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Assets, Including Short-Term Investments, Measured At Fair Value (Details)	Dec. 31, 2018USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	$ 37,404,750
Agency Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	5,658,600
US Treasury Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	29,821,150
Level 1
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	31,746,150
Level 1 | US Treasury Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	29,821,150
Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	5,658,600
Level 2 | Agency Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	5,658,600
Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	1,925,000
Certificates of Deposit | Level 1
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments	$ 1,925,000

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Additional Information (Details) - USD ($)	Oct. 16, 2018	Dec. 31, 2018	Dec. 31, 2017	Mar. 16, 2017
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial Liabilities transfer level 1 to level 2		$ 0
Financial Liabilities transfer level 2 to level 1		0
Financial Liabilities transfer Into Level 3		0
Financial Liabilities transfer out of Level 3		0
Biocon anti-dilution right			$ 775,842
IPO | Biocon
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Issuance of common stock, Shares	228,060
Biocon Anti-Dilution Right | Fair Value, Measurements, Recurring
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Biocon anti-dilution right		0	775,842	$ 0
Fair Value Measured Using Net Asset Value | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Investments in money market funds		$ 12,600,000	$ 0

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Activity for the Biocon Anti-Dilution Right Measured at Fair Value Using Level 3 Unobservable Inputs (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at March 16, 2017 (inception)		$ 775,842
Balance at December 31, 2017	$ 775,842
Fair Value, Measurements, Recurring | Biocon Anti-Dilution Right
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at March 16, 2017 (inception)		775,842
Issuance of liability	605,402
Changes in fair value	170,440	2,416,998
Balance at December 31, 2017	$ 775,842	0
Fair Value, Measurements, Recurring | IPO | Biocon Anti-Dilution Right
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Conversion to common stock upon IPO		$ (3,192,840)

Short-term Investments - Schedu

Short-term Investments - Schedule of Company's Short-Term Investments (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 37,399,471
Unrealized Gains	5,279
Short-term investments	37,404,750	$ 0
US Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	29,818,479
Unrealized Gains	2,671
Short-term investments	$ 29,821,150
US Treasury Securities | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturity (in years)	1 year
Agency Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 5,655,992
Unrealized Gains	2,608
Short-term investments	$ 5,658,600
Agency Securities | Minimum
Schedule Of Available For Sale Securities [Line Items]
Maturity (in years)	1 year
Agency Securities | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturity (in years)	5 years
Certificates of Deposit
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 1,925,000
Short-term investments	$ 1,925,000
Certificates of Deposit | Minimum
Schedule Of Available For Sale Securities [Line Items]
Maturity (in years)	1 year
Certificates of Deposit | Maximum
Schedule Of Available For Sale Securities [Line Items]
Maturity (in years)	5 years

Short-term Investments - Additi

Short-term Investments - Additional information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Short-term investments	$ 37,404,750	$ 0
Other than temporary impairment loss investments available for sale securities	$ 0
Minimum
Schedule Of Available For Sale Securities [Line Items]
Available for sale Securities debt maturities period	1 year
Maximum
Schedule Of Available For Sale Securities [Line Items]
Available for sale Securities debt maturities period	2 years

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Less accumulated depreciation and amortization	$ (6,224)	$ (122)
Property and equipment, net	63,515	2,077
Furniture And Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	23,283
Machinery & Lab Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	23,686
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 22,770	$ 2,199

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 122	$ 6,102
Disposal of property and equipment	$ 0	$ 0

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities Current [Abstract]
Accrued payroll and other employee benefits	$ 559,541	$ 15,548
Clinical studies	244,506
Other accruals	96,412	632
Preclinical studies	8,368	36,000
Accrued taxes		184,527
Accrued interest		88,372
Total accrued expenses	$ 908,827	$ 325,079

Collaboration And License Agr_2

Collaboration And License Agreements - Additional Information (Details) - USD ($)	Oct. 16, 2018	May 31, 2017	Dec. 31, 2018
Biocon Anti-Dilution Right | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of common stock outstanding shares issued in consideration for collaboration and license agreement		19.50%	19.50%
Issuance of liability		$ 605,402
Biocon | Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payments		30,000,000
Sales milestone payments		$ 565,000,000
Biocon | IPO
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock, Shares	228,060

Convertible Promissory Notes -

Convertible Promissory Notes - Additional Information (Details) - USD ($)	1 Months Ended		10 Months Ended	12 Months Ended
	Jun. 30, 2018	May 31, 2017	Dec. 31, 2017	Dec. 31, 2018
Debt Instrument [Line Items]
Interest expense			$ 379,385	$ 2,557,510
Convertible Promissory Notes
Debt Instrument [Line Items]
Interest expense			$ 379,385	2,557,510
Convertible Promissory Notes | Minimum
Debt Instrument [Line Items]
Gross proceeds from convertible promissory notes conversion, converted equity securities amount to be received				$ 15,000,000
Convertible Promissory Notes | IPO
Debt Instrument [Line Items]
Convertible promissory notes converted into common stock				878,834
Convertible Promissory Notes | Closing of Financing Occurs on or Prior to Six Month Anniversary of Issuance of Convertible Promissory Notes
Debt Instrument [Line Items]
Convertible promissory notes conversion price, percentage of per share price paid by investors for such securities				90.00%
Convertible Promissory Notes | Closing of Financing Occurs After Six Month Anniversary of Issuance of Convertible Promissory Notes
Debt Instrument [Line Items]
Convertible promissory notes conversion price, percentage of per share price paid by investors for such securities				80.00%
Convertible Promissory Notes | Founder Notes
Debt Instrument [Line Items]
Convertible promissory notes issued		$ 1,000,000
Accrued interest rate		6.00%
Mature period		1 year
Convertible Promissory Notes | Note Purchase Agreements
Debt Instrument [Line Items]
Convertible promissory notes issued	$ 9,407,474
Accrued interest rate	6.00%
Mature period	2 years

Convertible Promissory Notes _2

Convertible Promissory Notes - Summary of All Debt Obligations Recorded on Balance Sheet (Details) - Convertible Promissory Notes	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Convertible Promissory Notes	$ 7,807,474
Accrued discount	251,392
Total notes payable	$ 8,058,866

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($)	Nov. 15, 2018	Oct. 16, 2018	Nov. 30, 2018	Oct. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development					$ 1,333,721	$ 4,943,149
Net proceeds, after deducting underwriting discounts, commissions and related transaction costs						$ 64,475,457
Proceeds from issuance of common stock					$ 100
Number of shares reserved for issuance					1,189,773	2,126,877
Weighted-average fair value of options granted					$ 0	$ 5.79
Dividends paid						$ 0
2018 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance				2,229,773		1,363,119
Number of new shares approved for issuance under the plan				1,040,000
Equity incentive plan description						The number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2019 through January 1, 2028, in an amount equal to 5.0% of the total number of shares of the Company’s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors.
2018 Equity Incentive Plan | Common Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum options exercise price as percentage of fair market value of common stock						100.00%
Remaining vesting period						3 years
2018 Equity Incentive Plan | Common Stock Options | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage						25.00%
2018 Equity Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares that may be issued on exercise of ISO						6,689,319
2018 Equity Incentive Plan | Maximum | Common Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award expiration period						10 years
2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance				333,119
Number of shares underlying award granted under the plan				856,654
Unvested shares issued under early exercise						446,171
Unvested stock liability					$ 0	$ 300,000
2017 Equity Incentive Plan | Short Term Portion Of Unvested Stock Liability
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested stock liability						100,000
2017 Equity Incentive Plan | Long Term Portion Of Unvested Stock Liability
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested stock liability						$ 200,000
2018 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of new shares approved for issuance under the plan				343,275
Employee stock purchase plan description						The number of shares of the Company’s common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2019 through January 1, 2028, by the lesser of (1) 1.0% of the total number of shares of the Company’s common stock outstanding on the last day of the calendar month before the date of the automatic increase, and (2) 343,275 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (1) and (2)
2018 and 2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares underlying award granted under the plan						866,654
2018 and 2017 Equity Incentive Plan | Employee And Non Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to outstanding options					$ 0	$ 4,579,471
Expected recognition period of unrecognized compensation cost					0 years	3 years 8 months 4 days
Underwriters Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock	445,097		445,097
Proceeds from issuance of common stock	$ 5,800,000		$ 5,800,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock						446,171
Conversion of convertible securities, shares of common stock issued				878,834		878,834
Common Stock | IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock		4,670,000		4,670,000		5,115,097
Sale of stock, price per share		$ 14		$ 14
Net proceeds, after deducting underwriting discounts, commissions and related transaction costs		$ 58,700,000		$ 58,700,000
Founder Notes | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock					8,620,000
Sale of stock, price per share					$ 0.00001
Biocon
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock, price per share					$ 0.005
Biocon | IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock		228,060
Biocon | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock				228,060	2,088,074	228,060
Collaboration and License Agreement | Biocon Limited
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development					$ 9,689
Collaboration and License Agreement | Biocon Limited | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of stock					2,088,074
Sale of stock, price per share					$ 0.005

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of options vested during the period	$ 46,080
Cash received from options exercised during the period	291,091
Intrinsic value of options exercised during the period	$ 3,345,710
2018 and 2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted | shares	866,654
Number of Shares, Exercised | shares	(446,171)
Number of Shares, Ending Balance | shares	420,483
Weighted Average Exercise Price, Granted | $ / shares	$ 2.16
Weighted Average Exercise Price, Exercised | $ / shares	(0.66)
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 3.75
Weighted Average Remaining Contractual Term, Outstanding	9 years 8 months 1 day
Aggregate Intrinsic Value, Outstanding	$ 1,853,746

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 441,914
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense	250,701
General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 191,213

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) - Summary of Weighted-Average Assumptions Used to Determine Fair Value of Stock Option Grants (Details)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Risk-free interest rate	2.83%
Expected volatility	88.29%
Expected term (in years)	5 years 10 months 28 days
Expected dividend yield	0.00%

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) - Summary of Common Stock Reserved for Future Issuance (Details) - shares	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total common stock reserved for future issuance	2,126,877	1,189,773
Stock Options Issued and Outstanding
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total common stock reserved for future issuance	420,483
Awards Available Under 2017 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total common stock reserved for future issuance		1,189,773
Awards Available Under 2018 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total common stock reserved for future issuance	1,363,119
2018 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total common stock reserved for future issuance	343,275

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details) - Convertible Promissory Notes - Founder Notes	May 31, 2017USD ($)
Debt Instrument [Line Items]
Convertible promissory notes issued	$ 1,000,000
Chief Executive Officer
Debt Instrument [Line Items]
Convertible promissory notes issued	500,000
Chief Business Officer
Debt Instrument [Line Items]
Convertible promissory notes issued	$ 500,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Non-cancelable operating lease, expiration		2022-02
Rent expense of operating lease	$ 0	$ 49,255
Litigation expense		$ 0	$ 0

Commitments and Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments Required Under Non-Cancelable Leases (Details)	Dec. 31, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2019	$ 57,522
2020	58,914
2021	59,192
2022	9,865
Total minimum lease payments	$ 185,493

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Total Income Tax Provision Tax Rate to Statutory Federal Income Tax Rate (Details)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income taxes at statutory rates	34.00%	21.00%
State income tax, net of federal benefit	0.00%	0.00%
Permanent items	(10.92%)	(9.76%)
Tax law change - tax reform	(8.78%)	0.00%
Federal research credit	0.41%	1.68%
Change in federal valuation allowance	(14.71%)	(12.92%)
Effective rate	0.00%	0.00%

Income Taxes - Summary of Net D

Income Taxes - Summary of Net Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforward	$ 2,268,242	$ 248,222
Credits	333,527	43,162
Intangibles	184,847
Other	224,534	198,290
Total deferred tax assets	3,011,150	489,674
Valuation allowance	(3,010,878)	(489,585)
Total deferred tax assets, net of allowance	272	89
Deferred tax liabilities:
Property and equipment	(272)	(89)
Total deferred tax liabilities	(272)	(89)
Net deferred taxes	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Tax Credit Carryforward [Line Items]
Deferred tax assets, Valuation allowance	$ 489,585	$ 3,010,878
Increase in valuation allowance		$ 2,521,293
Federal and state net operating loss carry forwards, Expiration year		2037
Federal net operating loss carryover		$ 7,127,000
Operating loss carryforwards, Limitation of use		Federal net operating losses generated in 2018 carryover indefinitely and may generally be used to offset up to 80% of future taxable income
Tax credit carry forwards	43,162	$ 333,527
Tax credit carryforward, Expiration year		2037
Cumulative change in ownership percentage		50.00%
Cumulative change in ownership period		3 years
Reduction of deferred tax assets	$ (198,687)
Maximum
Tax Credit Carryforward [Line Items]
Operating loss carryforwards limitation rate on taxable income		80.00%
Federal
Tax Credit Carryforward [Line Items]
Federal tax loss carry forwards		$ 8,011,776
Tax credit carry forwards		305,035
State
Tax Credit Carryforward [Line Items]
Tax credit carry forwards		141,611
California
Tax Credit Carryforward [Line Items]
Foreign tax loss carry forwards		$ 8,176,000

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits – Beginning		$ 18,849
Gross decreases – tax positions in prior period		(11,310)
Gross increase – current-period tax positions	$ 18,849	81,789
Unrecognized Tax Benefits – Ending	$ 18,849	$ 89,328

Retirement Plan - Additional In

Retirement Plan - Additional Information (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Employer's matching contributions to 401(k) plan	$ 0	$ 0

Selected Quarterly Financial _3

Selected Quarterly Financial Data (unaudited) (Details) - USD ($)	1 Months Ended	3 Months Ended							10 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Operating expenses	$ (67,195)	$ (4,228,099)	$ (2,225,880)	$ (1,125,078)	$ (1,036,530)	$ (639,801)	$ (83,711)	$ (921,341)	$ 1,712,049	$ 8,615,587
Net loss	$ (67,195)	$ (4,991,893)	$ (4,916,423)	$ (1,765,363)	$ (1,576,796)	$ (1,106,357)	$ (141,025)	$ (947,297)	$ (2,261,874)	$ (13,250,475)
Net loss per share, basic and diluted	$ (0.01)	$ (0.31)	$ (0.44)	$ (0.16)	$ (0.15)	$ (0.10)	$ (0.01)	$ (0.10)	$ (0.22)	$ (1.09)

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event $ in Millions	Feb. 27, 2019USD ($)ft²
Subsequent Event [Line Items]
Area of office space leased | ft²	2,050
Lease commencement date	Mar. 1, 2019
Term of lease	2 years
Future minimum obligations under lease, 2019	$ 74,000
Future minimum obligations under lease, 2020	91,000
Future minimum obligations under lease, 2021	$ 15,000